NYXH

NYXH

USD

Nyxoah SA Ordinary Shares

$6.100+0.080 (1.329%)

Echtzeitkurs

Healthcare
Medical Instruments & Supplies
Belgien

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$6.020

Hoch

$6.200

Tief

$6.012

Volumen

0.01M

Unternehmensfundamentaldaten

Marktkapitalisierung

230.2M

Branche

Medical Instruments & Supplies

Land

Belgium

Handelsstatistiken

Durchschnittliches Volumen

0.14M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $5.55Aktuell $6.100Hoch $12.21

Ähnliche Nachrichten

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

Mehr anzeigen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

Mehr anzeigen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
Analyst Upgrades

Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14

Stifel analyst Jonathan Block maintains Nyxoah with a Buy and lowers the price target from $15 to $14.

Mehr anzeigen
Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14
GlobeNewswire

Conditional Issuance of Shares

INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"),

Mehr anzeigen
Conditional Issuance of Shares
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

Mehr anzeigen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $15 Price Target

HC Wainwright & Co. analyst Edward White reiterates Nyxoah with a Buy and maintains $15 price target.

GlobeNewswire

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET –